c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Dornase alfa for COVID-19: real-time meta-analysis of 3 studies

@CovidAnalysis, November 2026, Version 2V2 (V1 2025)

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Dornase alfa COVID-19 outcomes

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Files (RCT)−9%1.09 · 0.61–1.92death39 (n)88 (n)I-SPY COVID Files (RCT)−32%1.32 · 0.84–2.08no recov.39 (n)88 (n)I-SPY COVID Porter (RCT)−130%2.30 · 0.10–52.10death1/300/9COVASE Porter (RCT)53%0.47 · 0.06–3.86death30 (n)69 (n)COVASE Porter (RCT)10%0.90 · 0.11–7.63no disch.3/301/9COVASE Åkesson (SB RCT)−11%1.11 · 0.30–4.12death4/364/40 Åkesson (SB RCT)−2%1.02 · 0.62–1.69no recov.36 (n)40 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Dornase alfa
reduces riskDornase alfa
increases risk →

Fig. S1. All outcomes.

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Supplementary Data — Dornase alfa for COVID-19: real-time meta-analysis of 3 studies

Dornase alfa COVID-19 outcomes